Talking to stakeholders, scientists, patients about rare disease research.
Rarebase Remarks
Claim This Podcastby Rarebase
5.0(1 reviews)
5 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
Talking to stakeholders, scientists, patients about rare disease research.
Language
🇺🇲
Publishing Since
1/24/2022
Reach the team behind Rarebase Remarks
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
March 22, 2023
#5 - Joe Bellucci: High-throughput screening for drug discovery
<p>Our Director of High Throughput Biology, Joe Bellucci, Ph.D., walks us through advances in high-throughput screening and next generation sequencing that have enabled tailored and scalable approaches to rare disease research.</p>
January 7, 2023
#4 - Clayton Mellina: Engineering and AI in the biotech space
<p>Clayton Mellina is Director of Software Engineering at Rarebase. He is passionate about developing impactful applications of machine learning and computer vision. Before joining Rarebase, Clayton developed industrial computer vision applications such as automated visual inspection for manufacturing at Google Cloud.</p> <p>A few years ago, Clayton was diagnosed with a rare genetic disorder called NF2, which causes tumors to grow from his nerves. In this episode of Rarebase Remarks, Clayton discusses his personal experience with rare disease and how breakthrough technologies in machine learning and high throughput biology will drive a precision medicine revolution.</p>
April 26, 2022
#3 - Mike Graglia: Be humble and smart
<p>Onno & Lynsey recently caught up with Mike Graglia, Co-founder and Managing Director of the SynGAP Research Fund (SRF). SRF is a Rarebase collaborator, and Mike is a leading voice in the rare disease advocacy space. We are honored to feature Mike and share his insights on everything from fundraising tactics to prioritizing R&D efforts on behalf of his community.</p>
5 total episodes available
Deep-dive analytics for Rarebase Remarks
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Rarebase Remarks?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.